{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:14:28Z","timestamp":1790824468002,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06651-0","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T09:00:27Z","timestamp":1761210027000},"page":"5095-5110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Post-cytotoxic myeloid neoplasms: a comprehensive analysis of clinicopathologic, genetic profile, latency determinants, and potential prognostic predictors- a single centre study"],"prefix":"10.1007","volume":"104","author":[{"given":"Dina Sameh","family":"Soliman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehab","family":"Fareed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prem","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Akiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halima","family":"El-Omri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feryal","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"El Kourashy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Al-Sabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einas","family":"Al-Kuwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"issue":"31","key":"6651_CR1","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","volume":"33","author":"LS Granfeldt \u00d8stg\u00e5rd","year":"2015","unstructured":"Granfeldt \u00d8stg\u00e5rd LS, Medeiros BC, Sengel\u00f8v H, N\u00f8rgaard M, Andersen MK, Dufva IH et al (2015) Epidemiology and clinical signifcance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol 33(31):3641\u20133649","journal-title":"J Clin Oncol"},{"issue":"20","key":"6651_CR2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405","journal-title":"Blood"},{"key":"6651_CR3","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O, et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia 36:1703\u20131719","DOI":"10.1038\/s41375-022-01613-1"},{"key":"6651_CR4","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM et al (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140:1200\u20131228","journal-title":"Blood"},{"key":"6651_CR5","first-page":"4140","volume":"5","author":"AA Patel","year":"2021","unstructured":"Patel AA, Rojek AE, Drazer MW, Weiner H, Godley LA, Le Beau MM et al (2021) Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy. Blood Adv 5:4140\u20134148","journal-title":"Blood Adv"},{"issue":"5","key":"6651_CR6","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3390\/biomedicines12051054","volume":"12","author":"S Travaglini","year":"2024","unstructured":"Travaglini S, Marinoni M, Visconte V, Guarnera L (2024) Therapy-related myeloid neoplasm: biology and mechanistic aspects of malignant progression. Biomedicines 12(5):1054. https:\/\/doi.org\/10.3390\/biomedicines12051054","journal-title":"Biomedicines"},{"issue":"3","key":"6651_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.23908","volume":"90","author":"E Hulegardh","year":"2015","unstructured":"Hulegardh E, Nilsson C, Lazarevic V, Garelius H, Antunovic P, Rangert Derolf A et al (2015) Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish acute leukemia registry. Am J Hematol 90(3):208\u2013214","journal-title":"Am J Hematol"},{"issue":"3","key":"6651_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.blre.2016.11.002","volume":"31","author":"A Abou Zahr","year":"2017","unstructured":"Abou Zahr A, Kavi AM, Mukherjee S (2017) Therapy-related myelodysplastic syndromes, or are they? Blood Rev 31(3):119\u2013128. https:\/\/doi.org\/10.1016\/j.blre.2016.11.002","journal-title":"Blood Rev"},{"key":"6651_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1001\/jamaoncol.2018.5625","volume":"5","author":"LM Morton","year":"2019","unstructured":"Morton LM, Dores GM, Schonfeld SJ, Linet MS, Sigel BS, Lam CJK et al (2019) Association of chemotherapy for solid tumors with development of therapy-related myelodysplastic syndrome or acute myeloid leukemia in the modern era. JAMA Oncol 5:318\u2013325","journal-title":"JAMA Oncol"},{"key":"6651_CR10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/MOH.0000000000000316","volume":"24","author":"A Ganser","year":"2017","unstructured":"Ganser A, Heuser M (2017) Therapy-related myeloid neoplasms. Curr Opin Hematol 24:152\u2013158","journal-title":"Curr Opin Hematol"},{"issue":"9","key":"6651_CR11","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc.2017.60","volume":"17","author":"ME Mcnerney","year":"2017","unstructured":"Mcnerney ME, Godley LA, Le Beau MM (2017) Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer 17(9):513\u2013527","journal-title":"Nat Rev Cancer"},{"key":"6651_CR12","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood-2010-08-301713","volume":"117","author":"S Kayser","year":"2011","unstructured":"Kayser S, D\u00f6hner K, Krauter J, K\u00f6hne CH, Horst HA, Held G et al (2011) The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 117:2137\u20132145","journal-title":"Blood"},{"key":"6651_CR13","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/nature13968","volume":"518","author":"TN Wong","year":"2015","unstructured":"Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS et al (2015) Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 518:552\u2013555","journal-title":"Nature"},{"key":"6651_CR14","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1200\/JCO.20.02341","volume":"39","author":"DA Sallman","year":"2021","unstructured":"Sallman DA, DeZern AE, Garcia-Manero G et al (2021) Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes. J Clin Oncol 39:1584\u20131594","journal-title":"J Clin Oncol"},{"issue":"1","key":"6651_CR15","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL et al (2017) Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the association for molecular Pathology, American society of clinical Oncology, and college of American pathologists. J Mol Diagn 19(1):4\u201323","journal-title":"J Mol Diagn"},{"issue":"9","key":"6651_CR16","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1182\/blood.2022018236","volume":"141","author":"D Hiwase","year":"2023","unstructured":"Hiwase D, Hahn C, Tran ENH, Chhetri R, Baranwal A, Al-Kali A et al (2023) TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype. Blood 141(9):1087\u20131091. https:\/\/doi.org\/10.1182\/blood.2022018236","journal-title":"Blood"},{"issue":"5","key":"6651_CR17","doi-asserted-by":"publisher","first-page":"E80","DOI":"10.1002\/ajh.23966","volume":"90","author":"L Fianchi","year":"2015","unstructured":"Fianchi L, Pagano L, Piciocchi A et al (2015) Characteristics and outcome of therapy-related myeloid neoplasms: report from the Italian network on secondary leukemias. Am J Hematol 90(5):E80\u2013E85","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"6651_CR18","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1182\/blood-2019-127498","volume":"134","author":"VA Guerra","year":"2019","unstructured":"Guerra VA, Yuanqing Y, Hsu J, Wang F, Alfayez M, Morita K et al (2019) Comprehensive analysis of genotype and prior exposures in therapy-related myeloid neoplasms (t-MNs). Blood 134(Suppl 1):458","journal-title":"Blood"},{"issue":"21","key":"6651_CR19","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1002\/cncr.34453","volume":"128","author":"H Ha","year":"2022","unstructured":"Ha H, Kim HJ, Park JH (2022) Epidemiologic outlook of therapy-related myeloid neoplasms and selection of high-risk patients: a Korean nationwide study. Cancer 128(21):3888\u20133896","journal-title":"Cancer"},{"issue":"6","key":"6651_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/10245332.2017.1286539","volume":"22","author":"SW Maung","year":"2017","unstructured":"Maung SW, Burke C, Hayde J et al (2017) A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS\/AML) in Irish patients: a single centre experience. Hematology 22(6):341\u2013346","journal-title":"Hematology"},{"key":"6651_CR21","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2014.02.014","volume":"14","author":"H Medyouf","year":"2014","unstructured":"Medyouf H, Mossner M, Jann J-C, Nolte F, Raffel S, Herrmann C et al (2014) Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. Cell Stem Cell 14:824\u2013837","journal-title":"Cell Stem Cell"},{"key":"6651_CR22","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/nature08851","volume":"464","author":"MHG Raaijmakers","year":"2010","unstructured":"Raaijmakers MHG, Mukherjee S, Guo S, Zhang S, Kobayashi T, Schoonmaker JA et al (2010) Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 464:852\u2013857","journal-title":"Nature"},{"issue":"1","key":"6651_CR23","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41408-023-00821-x","volume":"13","author":"MV Shah","year":"2023","unstructured":"Shah MV, Tran ENH, Shah S, Chhetri R, Baranwal A, Ladon D, Shultz C et al (2023) TP53 mutation variant allele frequency of \u2265 10% is associated with poor prognosis in therapy-related myeloid neoplasms. Blood Cancer J 13(1):51","journal-title":"Blood Cancer J"},{"issue":"Supplement1","key":"6651_CR24","doi-asserted-by":"publisher","first-page":"5113","DOI":"10.1182\/blood-2019-131683","volume":"134","author":"DS Soliman","year":"2019","unstructured":"Soliman DS, Al-Sabbagh A, Ibrahim F, El-Omri H, Yassin M et al (2019) Local field radiotherapy induced therapy related myeloid neoplasms and bone marrow suppression. Blood 134(Supplement1):5113","journal-title":"Blood"},{"key":"6651_CR25","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1038\/s41375-018-0149-2","volume":"32","author":"JC Teepen","year":"2018","unstructured":"Teepen JC, Curtis RE, Dores GM, Berrington de Gonzalez A, van den Heuvel-Eibrink MM, Kremer LCM et al (2018) Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000\u20132014. Leukemia 32:2580\u20132589","journal-title":"Leukemia"},{"issue":"18","key":"6651_CR26","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1200\/JCO.2017.75.0232","volume":"36","author":"RJ Molenaar","year":"2018","unstructured":"Molenaar RJ, Sidana S, Radivoyevitch T et al (2018) Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer. J Clin Oncol 36(18):1831\u20131839","journal-title":"J Clin Oncol"},{"issue":"5","key":"6651_CR27","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41379-021-00958-9","volume":"35","author":"YC Liu","year":"2022","unstructured":"Liu YC, Illar GM, Al Amri R, Canady BC, Rea B, Yatsenko SA et al (2022) Therapy-related myeloid neoplasms with different latencies: a detailed clinicopathologic analysis. Mod Pathol 35(5):625\u2013631","journal-title":"Mod Pathol"},{"issue":"1","key":"6651_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","volume":"102","author":"SM Smith","year":"2003","unstructured":"Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J et al (2003) Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the university of Chicago series. Blood 102(1):43\u201352","journal-title":"Blood"},{"key":"6651_CR29","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/ajh.25814","volume":"95","author":"HJ Rogers","year":"2020","unstructured":"Rogers HJ, Wang X, Xie Y, Davis AR, Thakral B, Wang SA et al (2020) Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: a bone marrow pathology group study. Am J Hematol 95:799\u2013808","journal-title":"Am J Hematol"},{"issue":"5","key":"6651_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41408-020-0316-3","volume":"10","author":"B Samra","year":"2020","unstructured":"Samra B, Richard-Carpentier G, Kadia TM, Ravandi F, Daver N, DiNardo CD et al (2020) Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J 10(5):47","journal-title":"Blood Cancer J"},{"issue":"5","key":"6651_CR31","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/s00259-020-05127-9","volume":"48","author":"M Chantadisai","year":"2021","unstructured":"Chantadisai M, Kulkarni HR, Baum RP (2021) Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival. Eur J Nucl Med Mol Imaging 48(5):1390\u20131398","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"6651_CR32","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41375-020-0917-7","volume":"35","author":"A Kuendgen","year":"2021","unstructured":"Kuendgen A, Nomdedeu M, Tuechler H et al (2021) Therapyrelated myelodysplastic syndromes deserve specifc diagnostic Sub-classification and risk-stratification-an approach to classification of patients with MDS-pCT. Leukemia 35(3):835\u2013849","journal-title":"Leukemia"},{"key":"6651_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103607","volume":"171","author":"SA Strickland","year":"2022","unstructured":"Strickland SA, Vey N (2022) Diagnosis and treatment of therapy-related acute myeloid leukemia. Crit Rev Oncol Hematol 171:103607","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"6651_CR34","doi-asserted-by":"publisher","first-page":"e632","DOI":"10.1097\/HS9.0000000000000632","volume":"5","author":"S Khalife-Hachem","year":"2021","unstructured":"Khalife-Hachem S, Saleh K, Pasquier F, Willekens C, Tarabay A et al (2021) Molecular landscape of therapy-related myeloid neoplasms in patients previously treated for gynecologic and breast cancers. Hemasphere 5(9):e632. https:\/\/doi.org\/10.1097\/HS9.0000000000000632","journal-title":"Hemasphere"},{"issue":"8","key":"6651_CR35","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.bbmt.2020.04.004","volume":"26","author":"M Kida","year":"2020","unstructured":"Kida M, Usuki K, Uchida N, Fukuda T, Katayama Y, Kondo T et al (2020) Outcome and risk factors for therapy-related myeloid neoplasms treated with allogeneic stem cell transplantation in Japan. Biol Blood Marrow Transplant 26(8):1543\u20131551. https:\/\/doi.org\/10.1016\/j.bbmt.2020.04.004","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"6651_CR36","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.clml.2014.03.001","volume":"14","author":"A Quint\u00e1s-Cardama","year":"2014","unstructured":"Quint\u00e1s-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G et al (2014) A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 14(5):401\u2013410","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06651-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06651-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06651-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T23:04:51Z","timestamp":1763420691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06651-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6651"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06651-0","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study had an ethical approval from Hamad Medical Research Center under the protocol number # MRC-01-19-256.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The informed consent is waived in this study due to retrospective nature and the study involves minimal or no risk with de-identified subjects and the analysis utilized only publicly accessible data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}